Linked Life Data

2786518

Source:http://linkedlifedata.com/resource/pubmed/id/2786518

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1989-7-18
pubmed:abstractText
The in-vitro activity of a new penem FCE 22101 was evaluated in comparison with other antimicrobial agents against 966 aerobic and anaerobic Gram-negative and Gram-positive bacteria. FCE 22101 inhibited 90% of Enterobacteriaceae, Haemophilus influenzae, H. parainfluenzae, H. ducreyi, Neisseria gonorrhoeae, Branhamella catarrhalis, Staphylococcus aureus, Staph. epidermidis and group B streptococcus at concentrations of 0.12-4.0 mg/l. Pseudomonas aeruginosa was resistant with MIC90 of greater than 32 mg/l. Streptococcus faecalis displayed MIC90 of 16 mg/l. Bacteroides fragilis, Clostridium spp., Peptococcus spp. and Peptostreptococcus spp. were inhibited at concentrations of 0.25-2.0 mg/l. beta-Lactamase-producing or methicillin resistant bacteria did not have significantly elevated MICs. FCE 22101 was generally less active than imipenem but more active than other beta-lactam antibiotics examined.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0305-7453
pubmed:author
pubmed:issnType
Print
pubmed:volume
23 Suppl C
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
53-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
In-vitro activity of a new penem FCE 22101.
pubmed:affiliation
Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, Manitoba, Canada.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't